Increase in Pappalysin Levels Could Promote IGF-1 Bioavailability in Children with Prader-Willi Syndrome

February 20, 2024

The increase in free insulin-like growth factor (IGF)-I levels in prepubertal children with Prader-Willi Syndrome (PWS) treated with exogenous growth hormone (GH) could be caused by increased pregnancy-associated plasma protein A (PAPP-A, PAPP-A2) levels and a reduction in stanniocalcins (STC-1, STC-2), according to a study recently published in The Journal of Clinical Endocrinology & Metabolism. […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

Growth Issues Pediatric Health

←Pharma Fridays – February 16, 2024

Liraglutide Increases Insulin Sensitivity Independent of Weight Loss, Study Shows→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today